MFI: Emerging Digital Asset Strategy Includes Crypto

Novartis' remibrutinib, an oral BTK inhibitor, reduced annualized relapse rate by 35.2% and 31.2% in two phase 3 trials for relapsing multiple sclerosis (RMS) compared to teriflunomide. The trials also showed improvements in disability progression and MRI outcomes. Novartis plans to seek global regulatory approval for remibrutinib in RMS.

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 1

Kyverna Therapeutics presented updated Phase 1 trial data for miv-cel in progressive multiple sclerosis at MS Toronto 2026. Five patients showed stable or improved EDSS scores, with four sustaining benefits for over a year. The therapy demonstrated robust CAR T-cell expansion and a well-tolerated safety profile. Miv-cel is being investigated for autoimmune diseases, with over 100 patients treated to date.

AEON Biopharma plans to develop ABP-450 as a biosimilar to BOTOX®, targeting a Q4 2026 IND submission for a CMAP study. The company aims for full-label access across BOTOX®’s 12 indications, with FDA feedback suggesting supportive evidence from prior studies. ABP-450 is not yet FDA-approved.

Ardelyx reported real-world data at ASN Kidney Week 2026, showing serum phosphate reductions of 0.80–1.55 mg/dL at six months after XPHOZAH initiation. 16%–41% of patients reached <5.5 mg/dL, and 60%–70% remained on therapy at 180 days.

Johnson & Johnson's Acuvue Abiliti 1-Day lenses showed significant reduction in myopia progression in children over 3 years, with lower axial length growth (0.21 mm vs. 0.53 mm) and refraction change (–0.24 D vs. –0.98 D) compared to controls. Visual acuity remained 20/20 or better. The lenses are not FDA-approved but are approved in Canada.